Summary

Menopause-associated bone loss begins during perimenopause, ∼?2 years before the last menstrual period. This article presents data from the Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Alendronate on Bone Mineral Density and Bone Turnover in Perimenopausal Women With Low BMD poster [ICE/ENDO 2014. Poster LBSA-0269], first study to evaluate the efficacy of an antiresorptive agent on maintaining BMD in perimenopausal women.